FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2136405754> ?p ?o ?g. }

• W2136405754 endingPage "343" @default.
• W2136405754 startingPage "342" @default.
• W2136405754 abstract "HomeCirculation ResearchVol. 83, No. 3Vascular Endothelial Growth Factor and the Angiopoietins Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBVascular Endothelial Growth Factor and the Angiopoietins Working Together to Build a Better Blood Vessel Kevin G. Peters Kevin G. PetersKevin G. Peters Search for more papers by this author Originally published10 Aug 1998https://doi.org/10.1161/01.RES.83.3.342Circulation Research. 1998;83:342–343Angiogenesis is a complex multistep process by which new blood vessels are formed from the preexisting vasculature.12 Angiogenesis is a crucial event in normal embryonic development, and it contributes to the development and progression of a number of diseases, including cancer, arthritis, and diabetes. Conversely, insufficient growth of collateral vessels is a major clinical problem in atherosclerotic cardiovascular disease. The involvement of angiogenesis, or the failure of angiogenesis, in these important diseases has created a tremendous effort to define the molecular mechanisms by which the process is driven.Until recently, most of the work in the field has focused on polypeptide growth factors, such as fibroblast growth factor and vascular endothelial growth factor (VEGF), which are mitogenic for endothelial cells in vitro and produce an angiogenic response in vivo. Angiopoietins (Ang1 and Ang2) constitute a novel family of endothelial growth factors that are ligands for the endothelium-specific receptor tyrosine kinase, Tie2.3 Unlike other endothelial growth factors, stimulating Tie2 in cultured endothelial cells with either Ang1 or Ang2 does not produce a mitogenic response.3 Similar to other angiogenic factors, however, Ang1 can stimulate endothelial sprouting in vitro.4 Complicating matters, Ang2 appears to block the activation of Tie2 by Ang1, suggesting that it may be a naturally occurring inhibitor of Ang1/Tie2 activity.5 Despite the inability of angiopoietins to stimulate endothelial mitogenesis, disrupting the function of either Tie2 or Ang1 in transgenic mice resulted in early embryonic lethality secondary to defects in the developing vasculature.678 The defects included a decreased number of endothelial cells, simplification of the vascular branching pattern, and failure to recruit pericytes and smooth muscle cells. Consistent with its action as an Ang1/Tie2 inhibitor, overexpression of Ang2 resulted in vascular defects similar to those in the Ang1 or Tie2 knockouts.5 Taken together, these studies suggested that unlike other angiogenic growth factors, such as VEGF, which function during the earliest stages of vascular development, the angiopoietins play their major role at later stages of vascular development, ie, during vascular remodeling and maturation.On the basis of these data, Asahara et al,9 in an article in this issue of Circulation Research, hypothesized that angiopoietins may also be important for angiogenesis in adult tissues. In a mouse corneal micropocket assay, both Ang1 and Ang2 failed to stimulate an angiogenic response when administered alone. However, when coadministered with VEGF, both Ang1 and Ang2 augmented the formation of neovessels. Consistent with its hypothesized role in embryonic vascular development, coadministration of Ang1 resulted in an increase in total microvascular density as well as an increase in patent microvessels surrounded by smooth muscle cells. Interestingly, although Ang2 had insignificant effects on microvessel patency and smooth muscle cell recruitment, it increased both the length of microvessels and the number of migrating endothelial cells at the leading edge of the neovasculature. The authors suggest, as was previously hypothesized, that Ang2 augments angiogenesis by inhibiting Tie2, thereby “destabilizing” the vasculature and making it more responsive to angiogenesis initiators, such as VEGF.510 This is consistent with our recent finding11 that Tie2 is expressed and activated in the quiescent adult vasculature and the finding by Maisonpierre et al5 that Ang2 is expressed at the leading edge of proliferating vessels. Alternatively, Ang1 and Ang2 could activate Tie2 in fundamentally different ways, stimulating different signaling pathways and resulting in different biological responses. Just such a differential activation of an endothelial receptor has been reported for activation of EphB1 by different forms of its ligand, ephrin-B1.12 Although the differences in the biological effects between Ang1 and Ang2 need to be further defined at the molecular and cellular level, it is clear that the angiopoietin/Tie2 pathway importantly regulates angiogenesis in the adult cornea.An important message from the study of Asahara et al9 is that assembly of a functional vasculature likely requires the orchestration of a variety of endothelial growth factors and receptors, which play different roles at different stages of the process. Indeed, during the development of the embryonic vasculature, EphB4, a member of the Eph family of receptor tyrosine kinases, is expressed primarily in venous endothelium.13 Conversely, its ligand, ephrin-B2, is primarily expressed in arterial endothelial cells, suggesting a role for this system in mediating morphological and functional differences between the arterial and venous circulation. Like the Tie2 and Ang1 knockouts, disrupting the function of ephrin-B2 had no effect on the establishment of the primitive embryonic vasculature but resulted in defects in the remodeling of both the venous and arterial circulation. Neuropilin-1, a receptor for the collapsin/semaphorin family of neuronal cell guidance mediators, is expressed in the embryonic vasculature, and overexpression of neuropilin-1 resulted in hyperproliferation of the embryonic microvessels.14 Intriguingly, Soker et al15 have recently shown that neuropilin-1 is a coreceptor for VEGF, suggesting a functional role for neuropilin-1 in VEGF-mediated signal- ing. Finally, targeted disruption of a chemokine receptor, CXCR4, resulted in defects in the formation of large vessels that were localized to the gastrointestinal tract, demonstrating that organ-specific pathways may contribute to vascular remodeling.16 Whether or not these diverse pathways contribute to the angiogenic response in adult tissues will be an area of intense investigation.The realization that multiple pathways are likely required for the assembly of a functional vasculature has broad implications for the therapeutic modulation of angiogenesis. For example, it has already been shown that blocking either the VEGF pathway or the Tie2 pathway can inhibit tumor angiogenesis.1718 Since VEGF and Tie2 function at different stages of vascular development, it seems likely that inhibiting both pathways may be more effective than inhibiting each individually. By the same token, the results of the study of Asahara et al9 demonstrate that the combination of VEGF plus either of the angiopoietins has a salutary effect on vascular development. On the basis of their study, it is tempting to speculate that the angiopoietins will have the same effect on VEGF-induced and/or fibroblast growth factor–induced neovascularization in ischemic tissues.The opinions expressed in this article are not necessarily those of the editor or of the American Heart Association.FootnotesCorrespondence to Kevin G. Peters, MD, Duke University Medical Center, Research Drive, Box 3623, Durham, NC 27710. E-mail [email protected] References 1 Risau W. Mechanisms of angiogenesis. Nature.1997; 386:671–674.CrossrefMedlineGoogle Scholar2 Folkman J, D’Amore PA. Blood vessel formation: what is its molecular basis? Cell.1996; 87:1153–1155.CrossrefMedlineGoogle Scholar3 Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisonpierre PC, Yancopoulos GD. Isolation of angiopoietin-1, a ligand for the Tie-2 receptor, by secretion-trap expression cloning. Cell.1996; 87:1161–1169.CrossrefMedlineGoogle Scholar4 Koblizek TI, Weiss C, Yancopoulos GD, Deutsch U, Risau W. Angiopoietin-1 induces sprouting angiogenesis in vitro. Curr Biol.1998; 8:529–532.CrossrefMedlineGoogle Scholar5 Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science.1997; 277:55–60.CrossrefMedlineGoogle Scholar6 Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y, Gendron-Maguire M, Gridley T, Wolburg H, Risau W, Qin Y. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature.1995; 376:70–74.CrossrefMedlineGoogle Scholar7 Dumont DJ, Gradwohl G, Fong G-H, Puri MC, Gertsenstein M, Auerbach A, Breitman ML. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev.1994; 8:1897–1909.CrossrefMedlineGoogle Scholar8 Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD. Requisite role of angiopoietin-1, a ligand for the Tie-2 receptor, during embryonic angiogenesis. Cell.1996; 87:1171–1180.CrossrefMedlineGoogle Scholar9 Asahara T, Chen D, Takahashi T, Fujikawa K, Kearney M, Magner M, Yancopoulos GD, Isner JM. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res.1998; 83:233–240.CrossrefMedlineGoogle Scholar10 Hanahan D. Signaling vascular morphogenesis and maintenance. Science.1997; 277:48–50.CrossrefMedlineGoogle Scholar11 Wong AL, Haroon ZA, Werner S, Dewhirst MW, Greenberg CS, Peters KG. Tie-2 expression and phosphorylation in angiogenic and quiescent adult tissues. Circ Res.1997; 81:567–574.CrossrefMedlineGoogle Scholar12 Stein E, Lane AA, Cerretti DP, Schoecklmann HO, Schroff AD, Van Etten RL, Daniel TO. Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses. Genes Dev.1998; 12:667–678.CrossrefMedlineGoogle Scholar13 Wang HU, Chen Z-F, Anderson DJ. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell.1998; 93:741–753.CrossrefMedlineGoogle Scholar14 Kitsukawa T, Shimono A, Kawakami A, Kondoh H, Fujisawa H. Overexpression of a membrane protein, neuropilin, in chimeric mice causes anomalies in the cardiovascular system, nervous system and limbs. Development.1995; 121:4309–4318.CrossrefMedlineGoogle Scholar15 Soker S, Takashima S, Miao HO, Neufeld G, Klagsbrun M. Neuropilin-2 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell.1998; 92:735–745.CrossrefMedlineGoogle Scholar16 Tachibana K, Hirota S, Iizasa H, Yoshida H, Kawabata K, Kataoka Y, Kitamura Y, Matsushima K, Yoshida N, Nishikawa S, Kishimoto T, Nagasawa T. The chemokine receptor CSCR4 is essential for vascularization of the gastrointestinal tract. Nature.1998; 393:591–594.CrossrefMedlineGoogle Scholar17 Lin P, Polverini P, Dewhirst M, Shan S, Rao PS, Peters KG. Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie-2 in pathologic vascular growth. J Clin Invest.1997; 100:2072–2078.CrossrefMedlineGoogle Scholar18 Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature.1993; 362:841–844.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Williams P (2022) Quantile-specific heritability of serum growth factor concentrations, Growth Factors, 10.1080/08977194.2022.2049261, 39:1-6, (45-58), Online publication date: 28-Feb-2022. Le B, Raguraman P, Kosbar T, Fletcher S, Wilton S and Veedu R (2019) Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer Therapeutics, Molecular Therapy - Nucleic Acids, 10.1016/j.omtn.2018.11.007, 14, (142-157), Online publication date: 1-Mar-2019. Kim H, Ahn T, Kim C, Bae S, Kim H, Lee C, Kim T, Im J, Lee S, Son M, Lee M, Baek M and Jeong D (2017)(2017) Oncogenic function of angiopoietin-2 in vitro and its modulation of tumor progression in colorectal carcinoma, Oncology Letters, 10.3892/ol.2017.6203, 14:1, (553-560), Online publication date: 1-Jul-2017. El-Asrar M, Elbarbary N, Ismail E and Bakr A (2016) Circulating angiopoietin-2 levels in children and adolescents with type 1 diabetes mellitus: relation to carotid and aortic intima-media thickness, Angiogenesis, 10.1007/s10456-016-9517-6, 19:3, (421-431), Online publication date: 1-Jul-2016. Liu J, Wang X, Yang X, Yan Q, Wang S and Han W (2014) Investigating the role of angiogenesis in systemic lupus erythematosus, Lupus, 10.1177/0961203314556293, 24:6, (621-627), Online publication date: 1-May-2015. Belloni D, Marcatti M, Ponzoni M, Ciceri F, Veschini L, Corti A, Caligaris Cappio F, Ferrarini M and Ferrero E (2015) Angiopoietin-2 in Bone Marrow milieu promotes Multiple Myeloma-associated angiogenesis, Experimental Cell Research, 10.1016/j.yexcr.2014.10.017, 330:1, (1-12), Online publication date: 1-Jan-2015. Gui C, Li S, Nong Q, Du F, Zhu L and Zeng Z (2013) Changes of serum angiogenic factors concentrations in patients with diabetes and unstable angina pectoris, Cardiovascular Diabetology, 10.1186/1475-2840-12-34, 12:1, Online publication date: 1-Dec-2013. Cheng C, Chrifi I, Pasterkamp G and Duckers H (2013) Biological mechanisms of microvessel formation in advanced atherosclerosis: The big Five, Trends in Cardiovascular Medicine, 10.1016/j.tcm.2012.10.004, 23:5, (153-164), Online publication date: 1-Jul-2013. Lorbeer R, Baumeister S, Dörr M, Nauck M, Grotevendt A, Völzke H, Vasan R, Wallaschofski H and Lieb W (2014) Circulating angiopoietin-2, its soluble receptor Tie-2, and mortality in the general population, European Journal of Heart Failure, 10.1093/eurjhf/hft117, 15:12, (1327-1334), Online publication date: 1-Dec-2013. Huh D, Leslie D, Matthews B, Fraser J, Jurek S, Hamilton G, Thorneloe K, McAlexander M and Ingber D (2012) A Human Disease Model of Drug Toxicity–Induced Pulmonary Edema in a Lung-on-a-Chip Microdevice, Science Translational Medicine, 10.1126/scitranslmed.3004249, 4:159, Online publication date: 7-Nov-2012. Fawzy A, Gaafar R, Kasem F, Ali S, Elshafei M and Eldeib M (2012) Importance of serum levels of angiopoietin-2 and survivin biomarkers in non-small cell lung cancer, Journal of the Egyptian National Cancer Institute, 10.1016/j.jnci.2011.12.006, 24:1, (41-45), Online publication date: 1-Mar-2012. Zachariah J, Xanthakis V, Larson M, Vita J, Sullivan L, Smith H, Safa R, Peng X, Hamburg N, Levy D, Sawyer D, Mitchell G and Vasan R (2012) Circulating Vascular Growth Factors and Central Hemodynamic Load in the Community, Hypertension, 59:4, (773-779), Online publication date: 1-Apr-2012. Iribarren C, Phelps B, Darbinian J, McCluskey E, Quesenberry C, Hytopoulos E, Vogelman J and Orentreich N (2011) Circulating Angiopoietins-1 and -2, Angiopoietin Receptor Tie-2 and Vascular Endothelial Growth Factor-A as Biomarkers of Acute Myocardial Infarction: a Prospective Nested Case-Control Study, BMC Cardiovascular Disorders, 10.1186/1471-2261-11-31, 11:1, Online publication date: 1-Dec-2011. Rasul S, Reiter M, Ilhan A, Lampichler K, Wagner L and Kautzky-Willer A (2011) Circulating angiopoietin-2 and soluble Tie-2 in type 2 diabetes mellitus: a cross-sectional study, Cardiovascular Diabetology, 10.1186/1475-2840-10-55, 10:1, Online publication date: 1-Dec-2011. Cordeiro A, Figueiredo A, Tomada I, de Almeida H and Neves D (2010) Characterization of the Expression of Ang1, Ang2, and Tie2 in the Corpus Cavernosum of the Rat during Aging, Microscopy and Microanalysis, 10.1017/S1431927610094006, 16:6, (699-709), Online publication date: 1-Dec-2010. Lieb W, Zachariah J, Xanthakis V, Safa R, Chen M, Sullivan L, Larson M, Smith H, Yang Q, Mitchell G, Vita J, Sawyer D and Vasan R (2010) Clinical and Genetic Correlates of Circulating Angiopoietin-2 and Soluble Tie-2 in the Community, Circulation: Cardiovascular Genetics, 3:3, (300-306), Online publication date: 1-Jun-2010. Reiss Y, Knedla A, Tal A, Schmidt M, Jugold M, Kiessling F, Burger A, Wolburg H, Deutsch U and Plate K (2008) Switching of vascular phenotypes within a murine breast cancer model induced by angiopoietin-2, The Journal of Pathology, 10.1002/path.2484, 217:4, (571-580), Online publication date: 1-Mar-2009. Chen h, Shi Z, Wang S and Wu Q (2009) The effects of angiopoietin-2 on the growth of tongue carcinoma, British Journal of Oral and Maxillofacial Surgery, 10.1016/j.bjoms.2008.06.008, 47:1, (14-19), Online publication date: 1-Jan-2009. Naumnik W, Chyczewska E and Ossolinska M (2009) Serum Levels of Angiopoietin-1, Angiopoietin-2, and Their Receptor Tie-2 in Patients with Nonsmall Cell Lung Cancer During Chemotherapy, Cancer Investigation, 10.1080/07357900802672704, 27:7, (741-746), Online publication date: 1-Jan-2009. Park J, Choi H, Kim Y, Kim Y, Sheen S, Choi J, Lee H, Lee K, Chung W, Lee S, Park K, Hwang S, Lee K and Park K (2009) Serum angiopoietin-1 as a prognostic marker in resected early stage lung cancer, Lung Cancer, 10.1016/j.lungcan.2009.03.002, 66:3, (359-364), Online publication date: 1-Dec-2009. Qazi Y, Maddula S and Ambati B (2009) Mediators of ocular angiogenesis, Journal of Genetics, 10.1007/s12041-009-0068-0, 88:4, (495-515), Online publication date: 1-Dec-2009. Lester S, Bain J, Serio F, Harrelson B and Johnson R (2009) Relationship Between Gingival Angiopoietin-1 Concentrations and Depth of the Adjacent Gingival Sulcus, Journal of Periodontology, 10.1902/jop.2009.080643, 80:9, (1447-1453), Online publication date: 1-Sep-2009. Novotny N, Lahm T, Markel T, Crisostomo P, Wang M, Wang Y, Tan J and Meldrum D (2009) ANGIOPOIETIN-1 IN THE TREATMENT OF ISCHEMIA AND SEPSIS, Shock, 10.1097/SHK.0b013e3181862c63, 31:4, (335-341), Online publication date: 1-Apr-2009. Xie D, Annex B and Donatucci C (2008) Growth factors for therapeutic angiogenesis in hypercholesterolemic erectile dysfunction, Asian Journal of Andrology, 10.1111/j.1745-7262.2008.00372.x, 10:1, (23-27), Online publication date: 1-Jan-2008. Sullivan K, Bissonnette R, Yanagisawa H, Hussain S and Davis E (2007) Fibulin-5 functions as an endogenous angiogenesis inhibitor, Laboratory Investigation, 10.1038/labinvest.3700594, 87:8, (818-827), Online publication date: 1-Aug-2007. Wallner W, Sengenberger R, Strick R, Strissel P, Meurer B, Beckmann M and Schlembach D (2006) Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction, Clinical Science, 10.1042/CS20060161, 112:1, (51-57), Online publication date: 1-Jan-2007. Park J, Park K, Kim Y, Sheen S, Lee K, Lee H, Oh Y and Hwang S (2007) Serum Angiopoietin-2 as a Clinical Marker for Lung Cancer, Chest, 10.1378/chest.06-2915, 132:1, (200-206), Online publication date: 1-Jul-2007. Murugaiyan G, Martin S and Saha B (2007) CD40-induced countercurrent conduits for tumor escape or elimination?, Trends in Immunology, 10.1016/j.it.2007.08.010, 28:11, (467-473), Online publication date: 1-Nov-2007. Hess A, Hirchenhain J, Schanz A, Talbi S, Hamilton A, Giudice L and Krüssel J (2006) Angiopoietin-1 and -2 mRNA and protein expression in mouse preimplantation embryos and uteri suggests a role in angiogenesis during implantation, Reproduction, Fertility and Development, 10.1071/RD05110, 18:5, (509), . Scott B, Zaratin P, Gilmartin A, Hansbury M, Colombo A, Belpasso C, Winkler J and Jackson J (2005) TNF-α modulates angiopoietin-1 expression in rheumatoid synovial fibroblasts via the NF-κB signalling pathway, Biochemical and Biophysical Research Communications, 10.1016/j.bbrc.2004.12.180, 328:2, (409-414), Online publication date: 1-Mar-2005. Hidai C, Kawana M, Habu K, Kazama H, Kawase Y, Iwata T, Suzuki H, Quertermous T and Kokubun S (2005) Overexpression of theDel1 gene causes dendritic branching in the mouse mesentery, The Anatomical Record Part A: Discoveries in Molecular, Cellular, and Evolutionary Biology, 10.1002/ar.a.20247, 287A:2, (1165-1175), Online publication date: 1-Dec-2005. Oka N, Yamamoto Y, Takahashi M, Nishitani M, Kanayama H and Kagawa S (2005) Expression of angiopoietin-1 and -2, and its clinical significance in human bladder cancer, BJU International, 10.1111/j.1464-410X.2005.05358.x, 95:4, (660-663), Online publication date: 1-Mar-2005. Hwang S, Choi H, Kim K, Hong H, Koh G and Lee G (2005) Expression and purification of recombinant human angiopoietin-2 produced in Chinese hamster ovary cells, Protein Expression and Purification, 10.1016/j.pep.2004.09.005, 39:2, (175-183), Online publication date: 1-Feb-2005. Rhee J and Hoff P (2005) Angiogenesis inhibitors in the treatment of cancer, Expert Opinion on Pharmacotherapy, 10.1517/14656566.6.10.1701, 6:10, (1701-1711), Online publication date: 1-Oct-2005. Ng I, Tan W, Ng P and Lim J (2005) Hypoxia inducible factor-1α and expression of vascular endothelial growth factor and its receptors in cerebral arteriovenous malformations, Journal of Clinical Neuroscience, 10.1016/j.jocn.2005.02.005, 12:7, (794-799), Online publication date: 1-Sep-2005. Torimura T, Ueno T, Kin M, Harada R, Taniguchi E, Nakamura T, Sakata R, Hashimoto O, Sakamoto M, Kumashiro R, Sata M, Nakashima O, Yano H and Kojiro M (2004) Overexpression of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma, Journal of Hepatology, 10.1016/j.jhep.2004.01.027, 40:5, (799-807), Online publication date: 1-May-2004. Sun X, Liu X, Wu J, Cai X, Mou Y and Li J (2004) Expression and significance of angiopoietin-2 in gastric cancer, World Journal of Gastroenterology, 10.3748/wjg.v10.i9.1382, 10:9, (1382), . Wray C, Rilo H and Ahmad S (2005) Colon cancer angiogenesis and antiangiogenic therapy, Expert Opinion on Investigational Drugs, 10.1517/13543784.13.6.631, 13:6, (631-641), Online publication date: 1-Jun-2004. Fan F, Stoeltzing O, Liu W, McCarty M, Jung Y, Reinmuth N and Ellis L (2004) Interleukin-1β Regulates Angiopoietin-1 Expression in Human Endothelial Cells, Cancer Research, 10.1158/0008-5472.CAN-03-0407, 64:9, (3186-3190), Online publication date: 1-May-2004. Garcea G, Lloyd T, Gescher A, Dennison A, Steward W and Berry D (2004) Angiogenesis of gastrointestinal tumours and their metastases – a target for intervention?, European Journal of Cancer, 10.1016/j.ejca.2004.02.015, 40:9, (1302-1313), Online publication date: 1-Jun-2004. Rabinovsky E and Draghia-Akli R (2004) Insulin-like Growth Factor I Plasmid Therapy Promotes in Vivo Angiogenesis, Molecular Therapy, 10.1016/j.ymthe.2003.10.003, 9:1, (46-55), Online publication date: 1-Jan-2004. Emoto M, Charnock-Jones D, Licence D, Ishiguro M, Kawai M, Yanaihara A, Saito T, Hachisuga T, Iwasaki H, Kawarabayashi T and Smith S (2004) Localization of the VEGF and angiopoietin genes in uterine carcinosarcoma, Gynecologic Oncology, 10.1016/j.ygyno.2004.08.042, 95:3, (474-482), Online publication date: 1-Dec-2004. Nourhaghighi N, Teichert-Kuliszewska K, Davis J, Stewart D and Nag S (2003) Altered Expression of Angiopoietins During Blood-Brain Barrier Breakdown and Angiogenesis, Laboratory Investigation, 10.1097/01.LAB.0000082383.40635.FE, 83:8, (1211-1222), Online publication date: 1-Aug-2003. Kusumanto Y, Hospers G, Mulder N and Tio R (2009) Therapeutic angiogenesis with vascular endothelial growth factor in peripheral and coronary artery disease: a review, International Journal of Cardiovascular Interventions, 10.1080/14628840304612, 5:1, (27-34), Online publication date: 1-Jan-2003. Féraud O, Mallet C and Vilgrain I (2003) Expressional Regulation of the Angiopoietin-1 and -2 and the Endothelial-Specific Receptor Tyrosine Kinase Tie2 in Adrenal Atrophy: A Study of Adrenocorticotropin-Induced Repair, Endocrinology, 10.1210/en.2003-0099, 144:10, (4607-4615), Online publication date: 1-Oct-2003. Reinmuth N, Parikh A, Ahmad S, Liu W, Stoeltzing O, Fan F, Takeda A, Akagi M and Ellis L (2003) Biology of angiogenesis in tumors of the gastrointestinal tract, Microscopy Research and Technique, 10.1002/jemt.10258, 60:2, (199-207), Online publication date: 1-Feb-2003. Sfiligoi C, de Luca A, Cascone I, Sorbello V, Fuso L, Ponzone R, Biglia N, Audero E, Arisio R, Bussolino F, Sismondi P and De Bortoli M (2002) Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival, International Journal of Cancer, 10.1002/ijc.10851, 103:4, (466-474), Online publication date: 10-Feb-2003. Boedefeld W, Bland K and Heslin M (2003) Recent Insights Into Angiogenesis, Apoptosis, Invasion, and Metastasis in Colorectal Carcinoma, Annals of Surgical Oncology, 10.1245/ASO.2003.02.021, 10:8, (839-851), Online publication date: 1-Sep-2003. Ribatti D, Marzullo A, Nico B, Crivellato E, Ria R and Vacca A (2003) Erythropoietin as an angiogenic factor in gastric carcinoma, Histopathology, 10.1046/j.1365-2559.2003.01581.x, 42:3, (246-250), Online publication date: 1-Mar-2003. Schlembach D and Beinder E (2003) Angiogenetische Faktoren bei der Präeklampsie 54. Kongress der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe, 10.1007/978-3-642-18257-0_145, (530-532), . Stöltzing O, Ahmad S, Liu W, McCarty M, Fan F, Bucana C and Ellis L (2003) Inhibition von Tumor-Angiogenese und Gefäßpermeabilität durch Angiopoietin-1 Chirurgisches Forum 2003 für experimentelle und klinische Forschung, 10.1007/978-3-642-19024-7_27, (95-97), . Ratajska A, Myka M, Fiejka E, Józkowicz A and Dulak J (2002) Expression of Angiopoietins (-1 and -2) in Embryonic Rat Hearts during Coronary Vessel Development Cardiac Development, 10.1007/978-1-4615-0967-7_3, (33-44), . Sato T and Loughna S (2002) Vasculogenesis and Angiogenesis Mouse Development, 10.1016/B978-012597951-1/50014-7, (211-233), . Satchell S, Harper S, Tooke J, Kerjaschki D, Saleem M and Mathieson P (2002) Human Podocytes Express Angiopoietin 1, a Potential Regulator of Glomerular Vascular Endothelial Growth Factor, Journal of the American Society of Nephrology, 10.1681/ASN.V132544, 13:2, (544-550), Online publication date: 1-Feb-2002. Zhu W, MacIntyre A and Nicosia R (2002) Regulation of Angiogenesis by Vascular Endothelial Growth Factor and Angiopoietin-1 in the Rat Aorta Model, The American Journal of Pathology, 10.1016/S0002-9440(10)64242-3, 161:3, (823-830), Online publication date: 1-Sep-2002. Blumenthal R, Taylor A, Goldman L, Brown G and Goldenberg D (2002) Abnormal expression of the angiopoietins and Tie receptors in menorrhagic endometrium, Fertility and Sterility, 10.1016/S0015-0282(02)04276-0, 78:6, (1294-1300), Online publication date: 1-Dec-2002. Stoeltzing O, Ahmad S, Liu W, McCarty M, Parikh A, Fan F, Reinmuth N, Bucana C and Ellis L (2002) Angiopoietin-1 inhibits tumour growth and ascites formation in a murine model of peritoneal carcinomatosis, British Journal of Cancer, 10.1038/sj.bjc.6600598, 87:10, (1182-1187), Online publication date: 1-Nov-2002. Veale D and FitzGerald O (2002) Psoriatic arthritis, Best Practice & Research Clinical Rheumatology, 10.1053/berh.2002.0248, 16:4, (523-535), Online publication date: 1-Sep-2002. Bouhadir K and Mooney D (2010) Promoting Angiogenesis in Engineered Tissues, Journal of Drug Targeting, 10.3109/10611860108998775, 9:6, (397-406), Online publication date: 1-Jan-2001. Ahmad S, Liu W, Jung Y, Fan F, Reinmuth N, Bucana C and Ellis L (2001) Differential expression of angiopoietin-1 and angiopoietin-2 in colon carcinoma, Cancer, 10.1002/1097-0142(20010901)92:5<1138::AID-CNCR1431>3.0.CO;2-L, 92:5, (1138-1143), Online publication date: 1-Sep-2001. Fearon U and Veale D (2001) Pathways of cell activation in spondyloarthropathies, Current Rheumatology Reports, 10.1007/s11926-996-0015-5, 3:5, (435-442), Online publication date: 1-Oct-2001. KNOX A, CORBETT L, STOCKS J, HOLLAND E, ZHU Y and PANG L (2001) Human airway smooth muscle cells secrete vascular endothelial growth factor: up‐regulation by bradykinin via a protein kinase C and prostanoid‐dependent mechanism, The FASEB Journal, 10.1096/fj.01-0256com, 15:13, (2480-2488), Online publication date: 1-Nov-2001. Neeman M, Dafni H, Bukhari O, Braun R and Dewhirst M (2001) In vivo BOLD contrast MRI mapping of subcutaneous vascular function and maturation: Validation by intravital microscopy, Magnetic Resonance in Medicine, 10.1002/mrm.1118, 45:5, (887-898), Online publication date: 1-May-2001. Akeson A, Wetzel B, Thompson F, Brooks S, Paradis H, Gendron R and Greenberg J (2000) Embryonic vasculogenesis by endothelial precursor cells derived from lung mesenchyme, Developmental Dynamics, 10.1002/(SICI)1097-0177(200001)217:1<11::AID-DVDY2>3.0.CO;2-L, 217:1, (11-23), Online publication date: 1-Jan-2000. Wong M, Chan S, Fu K, Leung S, Cheung N, Yuen S and Chung L (2000) The angiopoietins, tie2 and vascular endothelial growth factor are differentially expressed in the transformation of normal lung to non-small cell lung carcinomas, Lung Cancer, 10.1016/S0169-5002(00)00118-5, 29:1, (11-22), Online publication date: 1-Jul-2000. Lingham R and Singh S (2000) Farnesyl-Protein Transferase: A New Paradigm for Cancer Chemotherapy, Advances in Discovery and Development of Natural Product Inhibitors Bioactive Natural Products (Part E), 10.1016/S1572-5995(00)80050-2, (403-472), . Devignot S, Sapet C, Duong V, Bergon A, Rihet P, Ong S, Lorn P, Chroeung N, Ngeav S, Tolou H, Buchy P, Couissinier-Paris P and Bozza P (2010) Genome-Wide Expression Profiling Deciphers Host Responses Altered during Dengue Shock Syndrome and Reveals the Role of Innate Immunity in Severe Dengue, PLoS ONE, 10.1371/journal.pone.0011671, 5:7, (e11671) August 10, 1998Vol 83, Issue 3 Advertisement Article InformationMetrics © 1998 American Heart Association, Inc.https://doi.org/10.1161/01.RES.83.3.342 Originally publishedAugust 10, 1998 KeywordsTie2endotheliumangiopoietinangiogenesiscollateral vesselPDF download Advertisement" @default.
• W2136405754 created "2016-06-24" @default.
• W2136405754 creator A5017209241 @default.
• W2136405754 date "1998-08-10" @default.
• W2136405754 modified "2023-09-27" @default.
• W2136405754 title "Vascular Endothelial Growth Factor and the Angiopoietins" @default.
• W2136405754 cites W1566059459 @default.
• W2136405754 cites W1679229092 @default.
• W2136405754 cites W1969328947 @default.
• W2136405754 cites W1970614272 @default.
• W2136405754 cites W1996430165 @default.
• W2136405754 cites W2000537146 @default.
• W2136405754 cites W2010638326 @default.
• W2136405754 cites W2012390831 @default.
• W2136405754 cites W2035595755 @default.
• W2136405754 cites W2066888615 @default.
• W2136405754 cites W2067817921 @default.
• W2136405754 cites W2134384575 @default.
• W2136405754 cites W2140067862 @default.
• W2136405754 cites W2140459348 @default.
• W2136405754 cites W2152215024 @default.
• W2136405754 cites W2344433860 @default.
• W2136405754 doi "https://doi.org/10.1161/01.res.83.3.342" @default.
• W2136405754 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9710128" @default.
• W2136405754 hasPublicationYear "1998" @default.
• W2136405754 type Work @default.
• W2136405754 sameAs 2136405754 @default.
• W2136405754 citedByCount "82" @default.
• W2136405754 countsByYear W21364057542012 @default.
• W2136405754 countsByYear W21364057542013 @default.
• W2136405754 countsByYear W21364057542014 @default.
• W2136405754 countsByYear W21364057542015 @default.
• W2136405754 countsByYear W21364057542016 @default.
• W2136405754 countsByYear W21364057542017 @default.
• W2136405754 countsByYear W21364057542019 @default.
• W2136405754 countsByYear W21364057542021 @default.
• W2136405754 crossrefType "journal-article" @default.
• W2136405754 hasAuthorship W2136405754A5017209241 @default.
• W2136405754 hasBestOaLocation W21364057541 @default.
• W2136405754 hasConcept C103041312 @default.
• W2136405754 hasConcept C126322002 @default.
• W2136405754 hasConcept C146285616 @default.
• W2136405754 hasConcept C167734588 @default.
• W2136405754 hasConcept C2776992346 @default.
• W2136405754 hasConcept C2777025900 @default.
• W2136405754 hasConcept C2779094623 @default.
• W2136405754 hasConcept C71924100 @default.
• W2136405754 hasConcept C86803240 @default.
• W2136405754 hasConcept C95444343 @default.
• W2136405754 hasConceptScore W2136405754C103041312 @default.
• W2136405754 hasConceptScore W2136405754C126322002 @default.
• W2136405754 hasConceptScore W2136405754C146285616 @default.
• W2136405754 hasConceptScore W2136405754C167734588 @default.
• W2136405754 hasConceptScore W2136405754C2776992346 @default.
• W2136405754 hasConceptScore W2136405754C2777025900 @default.
• W2136405754 hasConceptScore W2136405754C2779094623 @default.
• W2136405754 hasConceptScore W2136405754C71924100 @default.
• W2136405754 hasConceptScore W2136405754C86803240 @default.
• W2136405754 hasConceptScore W2136405754C95444343 @default.
• W2136405754 hasIssue "3" @default.
• W2136405754 hasLocation W21364057541 @default.
• W2136405754 hasLocation W21364057542 @default.
• W2136405754 hasOpenAccess W2136405754 @default.
• W2136405754 hasPrimaryLocation W21364057541 @default.
• W2136405754 hasRelatedWork W1782187318 @default.
• W2136405754 hasRelatedWork W1967988741 @default.
• W2136405754 hasRelatedWork W1970148025 @default.
• W2136405754 hasRelatedWork W1980772020 @default.
• W2136405754 hasRelatedWork W2057585528 @default.
• W2136405754 hasRelatedWork W2070070624 @default.
• W2136405754 hasRelatedWork W2160559914 @default.
• W2136405754 hasRelatedWork W3146659689 @default.
• W2136405754 hasRelatedWork W3206239442 @default.
• W2136405754 hasRelatedWork W3085114652 @default.
• W2136405754 hasVolume "83" @default.
• W2136405754 isParatext "false" @default.
• W2136405754 isRetracted "false" @default.
• W2136405754 magId "2136405754" @default.
• W2136405754 workType "article" @default.